Moonlake Immunotherapeutics DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
MoonLake Immunotherapeutics has issued its 2026 proxy statement detailing director elections, auditor ratification, and a proposed 5 million share increase to its equity incentive plan.
NASDAQ
MoonLake Immunotherapeutics announces its 2024 Annual General Meeting of Shareholders to be held on June 5, 2024, with voting open until June 4, 2024.
NASDAQ
MoonLake Immunotherapeutics has released its proxy statement for the 2025 Annual General Meeting of Shareholders, scheduled for June 5, 2025, covering director elections, auditor ratification, and executive compensation.
NASDAQ
MoonLake Immunotherapeutics announces its 2024 Annual General Meeting of Shareholders to be held on June 5, 2024, with voting open until June 4, 2024.
NASDAQ
DEF 14A: MoonLake Immunotherapeutics Sets Date for 2024 Annual General Meeting, Outlines Key Proposals
MoonLake Immunotherapeutics will hold its 2024 Annual General Meeting on June 5, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of future executive compensation votes.